Fibrocell Science — Biotech Showcase 2015
21 slides from Fibrocell Science's conference presentation, Jan 12, 2015
Slide 1: Fibrocell Corporate Presentation
Fibrocell Corporate Presentation David Pernock, Chairman & CEO Biotech Showcase 2015 January 12, 2015
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation contains, and our officers and representatives may from time to time make, statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forwar
Slide 3: Investment Highlights
Investment Highlights • Fibrocell is the scientific leader of autologous fibroblast therapy for skin and connective tissue diseases • Developing gene-therapies for orphan skin diseases using the autologous fibroblast cell as the delivery vehicle for the desired gene • Our lead gene-therapy program i
Slide 4: The Science of Autologous Fibroblasts
The Science of Autologous Fibroblasts • Fibroblasts repair tissue infrastructure by producing extracellular matrix proteins including collagen and growth factors • Most common cell in skin and connective tissue − Autologous cells reduce risk of patient rejection • Fibroblasts have distinct advantage
Slide 5: Gene Therapy Product Engine
Gene Therapy Product Engine Integrates Intrexon’s synthetic biology to develop gene therapies for orphan diseases using the autologous fibroblast as the delivery vehicle Autologous Fibroblast Product Engine BLA label extension in Phase II • Vocal Cord Scarring Autologous Fibroblast Platform Tech
Slide 6: Two Product Engines – Multiple Therapeutics in Development
Gene Therapy Product Engine Autologous Fibroblast Product Engine Two Product Engines – Multiple Therapeutics in Development Collection Culture Administration Vector Preparation Gene Packaging Gene Integration Fibrocell Proprietary Personalized Biologics Approach 6
Slide 7: Development Pipeline
Indication 2014 2015 2016 Recessive Dystrophic Epidermolysis Bullosa (RDEB) GM-HDF-COL7 Vocal Cord Scarring Linear Scleroderma Development Pipeline Lead Rare Disease Program Azficel-T sBLA Programs Phase II/III Phase I Phase II Primary Endpoint Phase III Product Optimization and PoC Studies/Pre-Clin
Slide 8: Orphan Indication Prioritization
Orphan Indication Prioritization Gene Therapy RDEB Problem/Solution Well Defined Orphan Indication Unmet Need Big Impact/Excellent Value Proposition Localized Approach Autologous Fibroblast Ideal Delivery Vehicle Technically Feasible Animal Model Evaluation Category RDEB 8
Slide 9: RDEB Gene Therapy Candidate
• Gene therapy: autologous fibroblast upregulated to produce collagen VII • Autologous dermal fibroblast (azficel-T) transfected with a vector containing the gene for COL7A1 ‐ Cells will be expanded, administered directly to the papillary dermis via injection • Potential advantages: ‐ Autologous the
Slide 10: Recessive Dystrophic Epidermolysis Bullosa
Disease Current Treatments Epidemiology • Devastating, progressive, painful blistering disease that leads to death • RDEB life expectancy: 30 years • Cause: A mutation in the COL7A1 gene which encodes for type VII collagen • Bandaging & antibiotics – up to $20,000 per month • Feeding tubes • Surgery
Slide 11: RDEB Gene Therapy Development
Phase I Clinical Study Initiation, 2H 2015 IND Filing, 1H 2015 Pre-Clinical Studies – in Progress Recombinant DNA Advisory Committee (RAC) Meeting, March 2015 Pre-IND Meeting with FDA Orphan Drug Approval RDEB Gene Therapy Development Complete Engineering Runs Develop Assays for Potency and Safety S
Slide 12: Rationale Supporting Our Approach in RDEB
• Multiple published studies in previous animal models4,5,6 demonstrate that fibroblasts genetically modified with COL7A1: ‐ Deposited collagen VII and formed anchoring fibrils at the dermal-epidermal junction ‐ Exhibited stable expression ‐ Corrected blistering • Autologous cells are preferred over
Slide 13: Rationale Supporting Our Approach in RDEB
• Precedent for FDA-allowed IND using GM cells to treat RDEB ‐ An NIH-funded Phase I clinical trial using autologous keratinocyte sheets genetically modified with COL7A1 to treat RDEB is ongoing ‐ Establishes a basis and precedent pathway for our Phase I clinical trial design for GM-HDF-COL7 ‐ The N
Slide 14: Transforming Lives of RDEB Patients
Transforming Lives of RDEB Patients 14
Slide 15: Linear Scleroderma
Disease Epidemiology • Excess production of extracellular matrix characterized by skin fibrosis and linear scars • The linear areas of skin thickening may extend to underlying tissue and muscle in children which may impair growth in affected legs and arms or forehead • Lesions appearing across joint
Slide 16: Vocal Cord Scarring
Disease Current Treatments Epidemiology Damage to the fibroblast layer causes scarring and edema which limits air flow and results in severe and significant limitations in voice quality, often loss of voice • Voice therapy • Surgery - Injection (collagen, fat, calcium, hyaluronic acid) - Implant (PT
Slide 17: Rationale Supporting Our Approach in Vocal Cord Scarring
Positive Phase I clinical trial results published in peer-reviewed journal11 • All patients completed the clinical trial, successive injections of autologous fibroblasts were well-tolerated, and no serious adverse events reported; n=5 • Statistically significant and sustained improvement: - Efficacy
Slide 18: Vocal Cord Scarring Phase II
• Trial initiated; Enrollment active • Multi-center trial: 3 major centers • Double-blind, randomized, placebo-controlled, 20 subjects • 4-month efficacy endpoint • FDA Validated Study Endpoints Vocal Cord Scarring Phase II 18
Slide 19: Financial and Corporate Information
• Cash position $44.2 million cash position at Q3-2014 • HQ facility: Exton, PA • ~50 employees • 40.9 million shares outstanding - 6.0 million warrants; 2.3 million options • Clean capital structure • Analyst research: - Wedbush Securities, Inc. — David Nierengarten, PhD - Griffin Securities, Inc.
Slide 20: Investment Highlights
Investment Highlights • Fibrocell is the scientific leader of autologous fibroblast therapy for skin and connective tissue diseases • Developing gene-therapies for orphan skin diseases using the autologous fibroblast cell as the delivery vehicle for the desired gene • Our lead gene-therapy program i
Slide 21: References
References 1 Petrof G., et. al. Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomised, vehicle-controlled trial. Brit J Dermatol. 2013 Nov;169(5):1025-33. 2 DEBRA International. What is EB Infographic. http://www.debra-internat